8-K: Heartflow Reports Strong Q3 Results, Raises 2026 Guidance

Heartflow, Inc. announced robust third quarter 2026 financial results, including a 57% year-over-year revenue increase and raised full-year guidance.

Summary

• Heartflow reported third quarter 2026 total revenue of $72.9 million, a 57% increase year-over-year.
• Gross margin improved to 83.6% (non-GAAP 83.8%), up from 76.5% (non-GAAP 76.8%) in the prior year.
• Net operating loss decreased to $13.8 million (non-GAAP $5.0 million) from $15.1 million (non-GAAP $11.1 million) in Q3 2025.
• Full-year 2026 revenue guidance was raised to $262 million $264 million (49%-50% growth), up from $246 million $250 million (40%-42% growth).
• Non-GAAP gross margin guidance for 2026 was also increased to approximately 82.5% from 82%.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved margins, and raised guidance, indicating robust operational performance and positive future prospects.

Positives

• Total revenue increased by 57% year-over-year to $72.9 million in Q3 2026.
• U.S. revenue grew by 60% year-over-year, indicating strong domestic market performance.
• Gross margin expanded significantly to 83.6% from 76.5% year-over-year, driven by increased case volumes and AI efficiency.
• Non-GAAP net operating loss improved to $5.0 million from $11.1 million year-over-year.
• Full-year 2026 revenue guidance was raised to $262-$264 million, representing substantial growth.
• Non-GAAP gross margin guidance for the full year was also raised.
• The company's installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan.
• Cash, cash equivalents, and investments totaled $253.0 million as of September 30, 2026.

Negatives

• The company reported a net operating loss of $13.8 million for the third quarter.
• Total operating expenses increased year-over-year to $74.8 million, primarily due to investments in sales, technology, and clinical research.
• Non-GAAP net loss was $2.7 million for the quarter.

Risks

• Healthcare providers may be unwilling to change their standard practice regarding the evaluation of coronary artery disease.
• Adoption of the Heartflow Platform may be negatively impacted if third-party payors do not cover or provide adequate reimbursement.
• The company faces significant competition in an environment of rapid technological change.
• The commercialization of Heartflow Plaque Analysis is nascent.
• Risks associated with the use and development of AI models.
• Risks related to failing to properly manage future growth.
• Disruption by catastrophic events.
• Dependence on information technology systems and potential security breaches.

Future Outlook

Full-year 2026 guidance has been raised to $262 million $264 million in total revenue, representing approximately 49% to 50% growth year-over-year. Non-GAAP gross margin is expected to be approximately 82.5%. The company expresses increased confidence in its path to profitability.

Management Comments

• "Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters," said John Farquhar, President and CEO of Heartflow.
• "Our core FFRCT business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan, with utilization broadening across a wider share of applicable CCTAs."
• "The CCTA market continues to grow rapidly and remains significantly underpenetrated."
• "Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again."
• "With continued momentum and a scaling business, we believe we are well-positioned to extend our market leadership, and we have increased confidence in our path to profitability."

Industry Context

StockSavvy.ai notes that Heartflow's strong performance aligns with the growing adoption of AI-driven diagnostic tools in the healthcare sector, particularly in cardiology. The company's focus on coronary artery disease (CAD) addresses a significant global health concern, and their raised guidance suggests they are capturing market share in an expanding segment.

Comparison to Industry Standards

• Heartflow's reported year-over-year revenue growth of 57% in Q3 2026 significantly outpaces the typical growth rates seen in many established medical device companies, which often range from single digits to low double digits.
• The gross margin of 83.6% is exceptionally high for a medical technology company, suggesting strong pricing power and efficient operations, potentially exceeding benchmarks set by companies focused on less specialized diagnostic software or hardware.
• While specific comparable companies are not detailed in the filing, Heartflow's focus on AI for CAD diagnosis places it in a rapidly evolving and competitive field. Companies like GE Healthcare, Siemens Healthineers, and Philips are also investing heavily in AI for medical imaging and diagnostics, though their product portfolios are broader.
• The company's stated goal of reaching profitability is a key metric. Many growth-stage medical technology companies operate at a loss for extended periods while investing in R&D and market expansion, making Heartflow's progress towards this goal a critical benchmark.

Legal Proceedings

• The filing mentions 'certain litigation expenses' in the non-GAAP adjustments, indicating ongoing or past legal matters, but provides no specific details.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved margins, and raised guidance, suggesting potential for increased shareholder value.
• Customers (Healthcare Providers): Continued access to and potential expansion of advanced AI diagnostic tools for CAD, improving diagnostic capabilities.
• Employees: Potential for continued investment in growth, technology, and research, possibly leading to job creation and development opportunities.
• Payors: Increased adoption may lead to greater scrutiny on reimbursement policies for AI-driven diagnostics.

Next Steps

• Continue to expand commercial presence to make the Heartflow solution more widely available.
• Further leverage AI efficiency initiatives in production.
• Continue investments in technology and clinical research.
• Host a conference call on November 12, 2026, to discuss Q3 financial results.

Key Dates

Recommendation

The company demonstrates strong operational execution with significant revenue growth and improved margins, leading to a raised guidance. However, the continued net operating losses and the inherent risks in a competitive, rapidly evolving medical technology market warrant a cautious 'hold' recommendation until profitability is more firmly established and sustained.

Keywords

Heartflow, FFRCT, Plaque Analysis, Coronary Artery Disease, AI, Medical Technology, Healthcare, Financial Results